{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:23:52Z","timestamp":1793114632551,"version":"4.5.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004169","name":"Meiji Seika Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004169","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"DOI":"10.1007\/s12325-026-03756-4","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T06:20:37Z","timestamp":1786688437000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Association Between Efficacy and Pharmacokinetics of DMB-3115 and its Originator Ustekinumab in Patients with Chronic Plaque Psoriasis: An Exposure\u2013Response Analysis"],"prefix":"10.1007","author":[{"given":"Hironori","family":"Konishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeyuki","family":"Shindo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Ishiwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8242-0812","authenticated-orcid":false,"given":"Jun","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"3756_CR1","unstructured":"European Medicines Agency. Imuldosa (ustekinumab). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/imuldosa. Accessed 9 Apr 2026."},{"key":"3756_CR2","unstructured":"European Medicines Agency. Stelara (ustekinumab). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/stelara. Accessed 9 Apr 2026."},{"key":"3756_CR3","unstructured":"US Food and Drug Administration. STELARA\u00ae (ustekinumab). Highlights of prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761044s010lbl.pdf. Accessed 9 Apr 2026."},{"key":"3756_CR4","unstructured":"Janssen Pharmaceutical K.K. Stelara\u00ae subcutaneous injection. Package insert. (Japanese). https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/GeneralList\/3999431. Accessed 9 Apr 2026."},{"key":"3756_CR5","doi-asserted-by":"publisher","first-page":"4681","DOI":"10.1007\/s12325-025-03290-9","volume":"42","author":"J Morita","year":"2025","unstructured":"Morita J, Fuhr R, Koernicke T, Cho N, Mencarini TT, Fushimi H. Pharmacokinetic bioequivalence, safety, and immunogenicity of DMB-3115, an ustekinumab biosimilar, and EU- and US-Stelara in healthy adult participants: a randomized, double-blind, single-dose study. Adv Ther. 2025;42:4681\u201395.","journal-title":"Adv Ther"},{"key":"3756_CR6","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jdin.2025.09.004","volume":"24","author":"K Vekovska","year":"2025","unstructured":"Vekovska K, Imko-Walczuk B, Tich\u00fd M, et al. A randomized, double-blind, phase 3 study to compare efficacy, safety, and immunogenicity between DMB-3115 and reference product ustekinumab in patients with moderate-to-severe chronic plaque psoriasis. JAAD Int. 2025;24:147\u201365.","journal-title":"JAAD Int"},{"key":"3756_CR7","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1177\/0091270009343695","volume":"50","author":"H Zhou","year":"2010","unstructured":"Zhou H, Hu C, Zhu Y, et al. Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis. J Clin Pharmacol. 2010;50:257\u201367.","journal-title":"J Clin Pharmacol"},{"key":"3756_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17020187","volume":"17","author":"AJ Yarur","year":"2025","unstructured":"Yarur AJ, Dervieux T, Ungaro R, et al. Ustekinumab drug clearance is better associated with disease control than serum trough concentrations in a prospective cohort of inflammatory bowel disease. Pharmaceutics. 2025;17:187.","journal-title":"Pharmaceutics"},{"key":"3756_CR9","first-page":"2271","volume":"132","author":"The Japanese Dermatological Association","year":"2022","unstructured":"The Japanese Dermatological Association. Guidance on the use of biologics in patients with psoriasis (2022). Jpn J Dermatol. 2022;132:2271\u201396 (Japanese).","journal-title":"Jpn J Dermatol"},{"key":"3756_CR10","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1053\/j.gastro.2018.01.043","volume":"154","author":"OJ Adedokun","year":"2018","unstructured":"Adedokun OJ, Xu Z, Gasink C, et al. Pharmacokinetics and exposure response relationships of ustekinumab in patients with Crohn\u2019s disease. Gastroenterology. 2018;154:1660\u201371.","journal-title":"Gastroenterology"},{"key":"3756_CR11","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1007\/s10620-023-07822-7","volume":"68","author":"T Straatmijer","year":"2023","unstructured":"Straatmijer T, Biemans VBC, Moes DJAR, et al. Ustekinumab trough concentrations are associated with biochemical outcomes in patients with Crohn\u2019s disease. Dig Dis Sci. 2023;68:2647\u201357.","journal-title":"Dig Dis Sci"},{"key":"3756_CR12","first-page":"110","volume":"113","author":"R G\u00f3mez Esp\u00edn","year":"2021","unstructured":"G\u00f3mez Esp\u00edn R, Nicol\u00e1s De Prado I, Gil Candel M, Gonz\u00e1lez Carri\u00f3n M, Rentero Redondo L, Iniesta Naval\u00f3n C. Association between ustekinumab trough concentrations and biochemical outcomes in patients with Crohn\u2019s disease. A real life study. Rev Esp Enferm Dig. 2021;113:110\u20135.","journal-title":"Rev Esp Enferm Dig"},{"key":"3756_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-021-01946-8","volume":"21","author":"JY Yao","year":"2021","unstructured":"Yao JY, Zhang M, Wang W, et al. Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn\u2019s disease: a Chinese real-world study. BMC Gastroenterol. 2021;21:380.","journal-title":"BMC Gastroenterol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03756-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03756-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03756-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T06:20:39Z","timestamp":1786688439000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03756-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":13,"alternative-id":["3756"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03756-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"assertion":[{"value":"28 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Hironori Konishi, Takeyuki Shindo, Kazuya Ishiwata, and Jun Morita are employees of Meiji Seika Pharma Co., Ltd., the manufacturer of DMB-3115.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The DMB-3115-1 study [European Union Clinical Trials Register (EudraCT), number 2018-004033-33] included healthy males and females\u00a0[\n                      \n                      ], the DMB-3115-2 study (ClinicalTrials.gov identifiers, NCT04785326; EudraCT number, 2020-005108-21) included patients with moderate-to-severe chronic plaque psoriasis\u00a0[\n                      \n                      ], and the DMB-3115-3 study (Japan Registry of Clinical Trials, number jRCT2071210135) included healthy Japanese males. All the studies were conducted in accordance with the Declaration of Helsinki, the International Council for Harmonization Good Clinical Practice guidelines, and the appropriate regulatory requirements. The protocol, its amendments, and informed consent documentation were reviewed and approved by the institutional review board at the site. All participants provided written informed consent prior to any study-specific procedures.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}